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1 Directorate of Public HealthSetting: Nigeria has the world’s fourth largest tuberculosis burden, and multidrug resistant
tuberculosis (MDR-TB) represents a serious public health problem.
Objectives: To describe the demography of TB patients and determine the susceptibility of
Mycobacterium tuberculosis isolates to the major TB drugs.
Methods: One hundred and thirty-seven newly diagnosed TB patients (26 (19%) being HIV
positive) from all age groups were recruited into the study. Each specimen was cultured
using BACTEC MGIT960, followed by inoculation and growth on Lowenstein–Jensen (LJ)
medium. Primary identification was carried out using an immunochromatographic tech-
nique (Capilia TB-Neo), and further confirmed by genotyping. Drug susceptibility testing
(DST) was carried out by the agar proportion method.
Results: Of the 97 pure mycobacterial cultures on LJ medium, 81 (83.5%) isolates were iden-
tified asM. tuberculosis complex, while 16 (16.5%) were Capilia negative. DSTwas carried out
on 58 isolates. The drug susceptibility pattern showed that resistance occurred in 16 (27.6%)
for streptomycin, 11 (19%) for isoniazid, 9 (16%) for rifampicin, and 10 (17.2%) for ethambu-
tol. Rifampicin monoresistance occurred in 2 (3.4%) cases. MDR (combined resistance to
isoniazid and rifampicin), also involving resistance to streptomycin and ethambutol,
occurred in 6/58 (10.3%) isolates; although laboratory cross-contamination could not be
excluded in 4/6 MDR strains with identical MIRU patterns characterized by consecutive
strain numbers. Considering that first out of these 4 isolates was not due to laboratory
carryover, the results of this study still report a minimal MDR-TB rate of 3/58 (5.2%) among
newly diagnosed TB patients in Cross River State, Nigeria.
Conclusions: An increase in drug resistance was observed in this study as compared with
previous studies in the country. Hence, introduction of culture in routine diagnostic myco-
bacteriology laboratories will prevent the emergence and dissemination of MDR-TB, while-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
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tion, thereby reducing mislabeling, unnecessary treatment, and drug toxicity for patients.
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Fig. 1 – Sex and age distribution of smear-positive patients.Globally, tuberculosis (TB) continues to pose major health
challenges that result in disability and death. Nigeria has
the world’s fourth largest TB burden; with nearly 460,000 esti-
mated new cases annually [1]. The country adopted the Di-
rectly Observed Treatment Scheme (DOTS) strategy for TB
control since 2003, but both the case detection and treatment
success rates are among the lowest of high-TB burden coun-
tries [2]. There were 3.3 million people living with HIV in the
country by the end of 2009, an estimated 3.6% of the popula-
tion [3,4], and about 21% of all TB patients were dually in-
fected with TB and HIV [5–7]. Anti-TB drug resistance
among TB patients in some countries has increased in the last
decade, progressing from multiple drug-resistance (MDR), to
extensive drug resistance (XDR), to extreme and total drug
resistance (TDR) [8,9]. In 2008, there were an estimated
440,000 new multidrug-resistant TB (MDR-TB) cases emerging
worldwide with 150,000 deaths, and it was estimated that in
2009, 3.3% of all new TB cases had MDR-TB [10]. However, pre-
cise information on drug-resistance patterns ofMycobacterium
tuberculosis complex is lacking for Cross River State, Nigeria.
Consequently, the present investigation was aimed to have
a first idea of drug resistance and demographic characteris-
tics of M. tuberculosis strains isolated from newly diagnosed
TB patients in this area.
Materials and methods
The study was carried out in three senatorial districts (north-
ern, central and southern) of the Cross River State, located in
the South-South part of Nigeria between June 2008 and May
2009. A total of 137 sputum samples were collected from new-
ly diagnosed smear-positive patients without any family or
previous history of TB. Both genders (age range <15 to
>64 years) recruited from major hospitals and TB care facili-
ties were retained for the study. Ethical approval and in-
formed medical consent were appropriately obtained for the
study.
Sputum specimens obtained from patients were preserved
using sodium carbonate (75 mg), and/or refrigerated until cul-
tured. Specimens were decontaminated using modified Petr-
off’s method, and cultured using BACTEC MGIT960 (Becton
Dickinson, Franklin Lakes, NJ 07417, USA). Smears were made
from isolates obtained from the BACTEC MGIT tubes, stained
using the Ziehl Neelsen staining method, and examined for
the presence of acid-fast bacilli (AFB). The growth on each
AFB positive MGIT tube was further inoculated into two
Lowenstein–Jensen (L–J) slants, one containing sodium
pyruvate. The cultures were examined twice weekly, and their
rate of growth and colonial morphologies were recorded.
Contaminated slants were further re-decontaminated and
re-cultured.Capilia TB-Neo (TAUNS Laboratories Inc., Japan) according to
manufacturer’s instructions (http://capilia.jp/english/capil-
ia_tb_neo.html) and further confirmed by genotyping ofM. tuber-
culosis complex isolates as reported [11].M. tuberculosis complex
isolates were tested for drug susceptibility against 0.2 lg/ml for
isoniazid (INH), 40 lg/ml for rifampicin (RIF), 8 lg/ml for strepto-
mycin (STR), and 2 lg/ml for ethambutol (ETH) using the propor-
tion method on Lowenstein–Jensen medium.
Results
Gender, age and HIV status of TB patients
More males (n = 86, 62.8%) than females (n = 51, 37.2%) were
encountered in this study. The highest frequency of disease
occurred in the age range between 15 and 44 years with a total
of 115 (83.9%) out of 137 cases. The age range of 25 to 34 years
had the highest number of cases (58/137, 42.3%) with 35/86
(40.7%) males and 23/51 (45.1%) females (Fig. 1). Twenty-six
(19%) of the 137 patients enrolled in this study were HIV posi-
tive, while 81 (59.1%) were HIV negative. Information on the
HIV status of 30 (21.9%) patients was not available at the time
of specimen collection.
Culture and primary identification
Following specimen workup, including microscopy by the
Ziehl Neelsen method, primary isolation on MGIT, and
subculture on LJ, a final working culture of 97 isolates was ob-
tained after recording 19 (13.9%) negative cultures, 6 (4.4%)
mislabeled vials, and discarding 15 (10.9%) heavily contami-
nated LJ slants. Using the immunochromatographic tech-
nique (Capilia TB-Neo) and genotyping, 81 (83.5%) were
identified as members of the M. tuberculosis complex [11],
and 16 (16.5%) isolates were Capilia negative.
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A total of 58/81 of the M. tuberculosis isolates obtained were
evaluated for drug sensitivity. Their susceptibility patterns
and the HIV status of the patients are shown in Table 1.
Thirty-five (60.3%) isolates were pansusceptible, and resis-
tance to one or more of the standard drugs was detected in
23 (39.7%) patients. Irrespective of resistance combinations,
16 (27.6%) isolates were resistant to streptomycin, 11 (19%)
to isoniazid, 9 (16%) to rifampicin, and 10 (17.2%) to ethambu-
tol. Among the three HIV positive patients with drug
resistance, two were monoresistant to streptomycin and rif-
ampicin, and one was resistant to all four TB drugs (p = 0.7).
Globally, MDR occurred in six isolates in this study; all the
six strains were found to be resistant to all first-line anti-TB
drugs (FLD). However, 4/6 of these MDR strains shared an
identical MIRU (mycobacterial interspersed repetitive unit)
pattern 223315153321 which corresponded to MIRU Interna-
tional Type MIT266. Since all these four strains were charac-
terized by consecutive strain numbers, laboratory cross-
contamination could not be excluded in these strains [11].
Nonetheless, considering that the first out of these four iso-
lates was not due to laboratory carryover, a minimal MDR-
TB rate of 3/58 (5.2%) is still reported among newly diagnosed
TB patients in Cross River State, Nigeria.
Discussion
With 86 males and 51 females, globally there were 1.7 times
more males than females in this study, an observation which
is in agreement with the fact that male gender has been iden-
tified as a risk factor for TB [12–14]. Ninety-five percent of the
TB patients in this study were aged between 15 and 54 years –Table 1 – Drug susceptibility patterns of isolates and HIV status
Drugs M. tuberculosis
(n = 58)
Pansusceptible 35
Monoresistance
STRe 7
INHf 2
RIFg 2
ETHh 2
Resistance to two drugs
STR + INH 1
INH + ETH 1
STR + RIF 1
Resistance to three drugs
STR + INH + ETH 1
Multidrug resistance
STR + INH + RIF + ETH 6
a Human immunodeficiency virus.
b Positive.
c Negative.
d Unknown.
e Streptomycin.
f Isoniazid.
g Rifampicin.
h Ethambutol.in agreement with the observation that more than 75% of TB-
related disease and deaths occur among people in this age
range which is also the most economically active segment
of the population [15]. Indeed, TB affects the most productive
age group worldwide [10]; and interestingly, of the 51 female
TB patients in this study, 44 (86.3%) were aged between 15
and 44 years. Lastly, 20% of the TB patients in this study were
HIV positive (despite the fact that 22% did not know their HIV
status). Currently in Nigeria, 79% of tested TB patients know
their HIV status and 25% are HIV-positive (WHO TB data con-
sulted on October 15, 2011; http://www.who.int/tb/country/
en/index.html).
Only cases of primary drug resistance are assumed to be
owing to transmission of drug-resistant strains. In this study,
none of the patients had any history of prior anti-TB treat-
ment. Drug resistance irrespective of reported prior drug
intake in this study occurred in about 40% of cases. This is
similar to reports in Chad, a neighboring country, where
61% of isolates were susceptible to all drugs, and 39% were
resistant to at least one drug [16]. Other studies have shown
that a steady increase in drug resistance in the country is a
reality. Unpublished data carried in Zaria (Northern Nigeria)
among newly diagnosed TB patients confirmed this fact
(19% and 13% for isoniazid and streptomycin, respectively,
in 1991, against 29% and 14% by 2006; [17,18]). In the present
study, resistance to streptomycin was recorded at 27.6%;
similar high levels of resistance to streptomycin have been
reported in neighboring Cotonou (Benin Republic), as well as
in several other African countries, which may be partially
related to the widespread use of low-cost aminoglycosides
to treat respiratory infections other than TB [19,20].
Similarly, 19% of primary resistance to isoniazid in this
study is higher as compared with other African countriesof patients in Cross River State.
% HIVa status
Posb Negc Unkd
60.3 6 20 9
12.1 1 6 –
3.4 – 2 –
3.4 1 1 –
3.4 – 1 1
1.7 – 1 –
1.7 – – 1
1.7 – 1 –
1.7 – 1 –
10.3 1 2 3
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nea (12.5%; [22]) and Ethiopia (8%; [23]). Monoresistance to iso-
niazid is significantly more prevalent than monoresistance to
rifampicin and MDR-TB. Based on the most recent data, it is
estimated that 13.3% of all TB cases globally involve isoniazid
monoresistance vs. 0.6% for rifampicin, while 5.3% are MDR-
TB [23]. Thus, the high rates of resistance to isoniazid and rif-
ampicin that are the backbone of any successful TB treatment
program, as well as a minimal MDR-TB rate of 5.2% among
newly diagnosed TB patients in Cross River State, Nigeria,
are particularly worrisome.
The MDR-TB strains in this study were resistant to two
other drugs (streptomycin and ethambutol). Considering the
advent of extensively drug resistant TB (XDR-TB), dissemina-
tion of such strains poses a threat to the control of TB in the
region. However, unlike the global observation of 5.3% MDR
rate, low estimates of MDR-TB among new TB cases are being
observed in Nigeria by the WHO (currently at 2.2% as con-
sulted on October 15, 2011; http://www.who.int/tb/country/
en/index.html), which may be an underestimate given the
low level of culture and drug susceptibility testing carried
out in the country. Recently, a survey has shown an MDR
occurrence of 13% in Nigeria, with all the isolates being resis-
tant to all four first-line drugs [24]. However, patients in this
latter study were not differentiated as new or re-treatment
cases, as opposed to this study in which all the patients were
newly diagnosed.
Last but not least, laboratory cross-contamination was
equally recorded in the present study. Considering that DOTS
(Directly Observed Treatment Short-course) policy is mainly
based on smear microscopy alone, and the fact that sputum
culture is not routinely carried out in Nigeria, the extent of
cross-contamination cannot be reliably estimated. The usual
rate of cross-contamination in a routine clinical mycobacteri-
ology laboratory remains often unknown, since it requires
parallel genotyping [25]. Indeed, such a phenomena would
have been unrecognized in this study had it not been for ret-
rospective genotyping of the isolates [11], which revealed that
during the period of sample collection (within 1 week),
smears were handled by an inexperienced young graduate in-
tern who did not properly flame the wire loop leading to a lab-
oratory carryover. In this regard, several factors have been
shown to contribute to laboratory contamination and/or car-
ryover, including new personnel in the laboratory, faulty tech-
nique, and an increase in the number of specimens processed
[25]. False-positive results for TB are a matter of concern be-
cause of the clinical, therapeutic, and social impacts of the
misdiagnosis of TB, as well as the economic load associated
with each misdiagnosed case of TB [26].
In conclusion, the present study carried out in Cross River
State in Nigeria shows an increase in M. tuberculosis drug
resistance which may be reflecting a similar trend in the
whole country. The rise in MDR-TB highlights the urgent need
to strengthen national TB control programs, particularly in
settings with high HIV prevalence, like Nigeria. As in most
of Africa, treatment of TB in Nigeria is based on simple smear
microscopy results. The isolation of about 17% of nontubercu-
lous mycobacteria [27], and the treatment of such patients
with anti-tuberculous drugs, coupled with the use of strepto-
mycin in the treatment of respiratory tract infections otherthan TB may contribute to the rise in drug resistance seen
in this study and elsewhere. Nigeria is currently trailing
behind many countries in providing adequate laboratory
infrastructure for surveillance of drug resistant strains. This
study, therefore, pleads in favor of introduction of more
reliable diagnostic methods involving culture and rapid
molecular speciation in Nigeria as well as other African
countries.
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